A dietary supplement quality agreement should define who establishes specifications, approves components and suppliers, reviews production records, investigates deviations, releases finished batches, manages changes, handles complaints, and maintains required records. It should turn shared expectations into named responsibilities, decision rights, evidence, and escalation paths.
The agreement does not transfer a brand’s legal obligations to a contract manufacturer. FDA’s dietary supplement CGMP guide says a distributor that uses a contract manufacturer still needs to know what and how manufacturing activities are performed so it can decide whether the packaged product conforms to established specifications.
Why Use a Separate Quality Agreement?
A purchase order answers commercial questions. A quality agreement answers operational quality questions. It should align the brand, manufacturer, laboratories, packaging vendors, and other parties before a batch is in motion.
FDA’s drug contract-manufacturing guidance describes quality agreements as written arrangements that define each party’s CGMP activities and recommends keeping them separate, or at least severable, from commercial contracts. That guidance is for drugs, not dietary supplements, but the document-separation principle is a useful model. Supplement agreements must be built around 21 CFR Part 111 and the actual services in scope.
A clear agreement reduces the chance that both parties assume the other owns the same critical decision.
Which Products, Sites, and Services Are in Scope?
List the legal entities, manufacturing sites, product names or families, dosage forms, markets, and activities covered. Identify whether the engagement includes formulation, ingredient sourcing, manufacturing, packaging, labeling, storage, testing, stability work, release, fulfillment, or complaint support.
Also identify third parties. If an outside laboratory performs identity, microbial, heavy-metal, or potency testing, the agreement should say who qualifies the lab, orders tests, reviews results, pays for retests, and receives complete reports.
Scope should be specific enough that a new team member can tell whether a task belongs inside the agreement.

Who Establishes and Approves Specifications?

FDA requires specifications at multiple stages, including components, in-process production, finished batches, labels, and packaging. The agreement should name who drafts each specification, who reviews it, who approves it, and how revisions are controlled.
For components, define identity, purity, strength, composition, and contaminant limits as applicable. For finished products, connect the specification to label claims, serving size, physical attributes, microbial limits, and other release criteria. Packaging specifications should address suitability and the correct label.
The decision rule must be explicit: no material or finished batch moves forward until the responsible quality personnel have documented the required approval.
How Will Suppliers and Components Be Controlled?
State who approves suppliers, what qualification evidence is required, and how often qualification is reviewed. If the manufacturer relies on a supplier certificate of analysis for anything other than identity, document the qualification and verification approach required by the applicable rule.
Define receipt, quarantine, sampling, identity testing, status labeling, storage, and rejection. Clarify who can approve a substitution and whether the brand must consent before a component source, grade, country of origin, or specification changes.
Supplier control belongs in the quality system, not in an informal email chain.
What Records Must Be Created and Shared?
List the master manufacturing record, batch production record, test results, certificates of analysis, packaging and label reconciliation, cleaning or line-clearance evidence, deviation records, release documentation, and change-control records that apply.
The agreement should say which party owns the original, which party receives copies, the delivery format, retention period, access conditions, and response time for a legitimate request. Avoid vague language such as “records available on request” when the brand needs defined review rights before release.
Audit rights should be practical. State notice, frequency, confidentiality, scope, remote-document options, and how critical findings will be addressed.
Who Reviews Deviations, OOS Results, and CAPA?
Define the difference between a deviation, nonconformance, complaint, out-of-specification result, and out-of-trend result for this relationship. Name the party that opens the investigation, approves the investigation plan, assesses product impact, and decides whether reprocessing, rejection, or additional testing is appropriate.
Retesting should never be an automatic way to replace an unfavorable result. The agreement should require a scientifically sound investigation and preserve all original data.
For corrective and preventive action, set ownership, due dates, effectiveness checks, and escalation when an action is overdue.
How Are Changes Approved?
Create a change-notification matrix. Formula, component source, specification, process, equipment, site, test method, packaging, artwork, and label changes can have different approval needs. Define which changes require prior written brand approval and which only require notification.
Include enough lead time for regulatory, stability, inventory, and artwork consequences. Emergency changes need a defined exception process with documented risk assessment and retrospective approval.
No one should discover a material product change by seeing the next shipment.

Who Releases the Batch?
Name the manufacturer’s quality-control release responsibilities and the brand’s final distribution decision. Define the release packet and the exact evidence that must be complete before approval.
If the brand delegates a release task, document the delegation and oversight. Do not use the agreement to imply that FDA has approved the product or facility. Facility registration and third-party certification have different meanings and scopes.
Release is a documented decision, not the absence of an objection.
How Are Complaints, Serious Adverse Events, Recalls, and Returns Handled?
Specify intake routes, notification deadlines, investigation roles, sample handling, record sharing, trend review, and regulatory reporting responsibilities. Serious adverse event obligations and recall decisions require prompt, role-specific escalation.
Define who controls customer communications, distributors, regulators, and public statements. Include after-hours contacts and a current call tree. Run a mock trace or recall exercise at an agreed interval when appropriate to the product and risk.
A good agreement protects response time by deciding authority before an incident.
Frequently Asked Questions
No. A supply agreement covers commercial terms. A quality agreement defines quality-system responsibilities, records, approvals, and escalation. They should be coordinated but separable.
Part 111 sets CGMP responsibilities and records, but it does not make the title the point. The agreement is a practical control for allocating responsibilities without replacing either party’s legal duties.
No. FDA states that a distributor using a contract manufacturer still has obligations to understand the work and make conformity and release decisions.
It should identify approved methods or controlled references and define who can change them. The operational detail may live in specifications or procedures incorporated by reference.
Set a defined periodic review and trigger review after material changes, serious investigations, audit findings, or changes in law, sites, services, or products.
Build the Agreement Around Real Decisions
Start with the actual product, process, and parties. Assign every approval, record, notification, and escalation to a named role. Then make the agreement consistent with the master service agreement, specifications, procedures, and batch-release workflow.
Brands preparing a manufacturing discussion can review CPack Manufacturing’s supplement manufacturing capabilities and certifications, then use the quote page to share format, formula status, quantity, packaging, and target timing. Ask counsel and qualified regulatory professionals to review the final agreement for the specific relationship.